GPP
VERV

Great Point Partners’s Verve Therapeutics VERV Stock Holding History

Great Point Partners’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300,000
Closed -$5.8M – 52
2022
Q4 		$5.8M Buy
+300,000
New +$7.95M 1.14% 32
2021
Q3 		– Sell
-35,000
Closed -$2.11M – 42
2021
Q2 		$2.11M Buy
+35,000
New +$1.45M 0.44% 30

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Great Point Partners's VERV Position: Q1 2023 in Review

Great Point Partners sold out of Verve Therapeutics (VERV) in Q1 2023, closing a stake of 300,000 shares — an estimated $5.8M sold.

Great Point Partners first reported a position in VERV in Q2 2021 and held it in 2 quarters. The position peaked at $5.8M in Q4 2022. 125 funds tracked by Wall St. Rank hold VERV as of Q1 2023.

  • Great Point Partners reported no remaining Verve Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Great Point Partners sold 300,000 Verve Therapeutics shares in Q1 2023, an estimated $5.8M.
  • Great Point Partners first reported a position in Verve Therapeutics in Q2 2021 and held it in 2 quarters.
  • Great Point Partners's Verve Therapeutics position peaked at $5.8M in Q4 2022.
  • 125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2023.

Based on Great Point Partners's 13F filing for Q1 2023, filed 15 May 2023.